CLSN// Phase 3 interim data this Q = Multibagger Potential

[BiotechMaster]

This is the perfect time to load up the truck before the BIG News coming .

Phase 3 interim data for their potential blockbuster Thermodox + NDA submission + New Partnership all this News coming very soon .

See you guys in the Double Digits before year end .GLTA


Celsion (CLSN)

Market Cap : 38 M
Price : 2.90

Shares Out: 14 M // 8 M shares owned by Insiders/Institutions


.........
Some Slides from Cowen Presentation (March 2011)

Phase 3 interim analysis this Q
http://www.wsw.com/webcast/cowen3/clsn/2__Slide15.JPG

Rolling NDA + Priority review in 2011
http://www.wsw.com/webcast/cowen3/clsn/2__Slide6.JPG

Multibillion Dollar Potential for Thermodox
http://www.wsw.com/webcast/cowen3/clsn/2__Slide21.JPG

Near Term Milestones
http://www.wsw.com/webcast/cowen3/clsn/2__Slide24.JPG

Mega Pipeline
http://www.wsw.com/webcast/cowen3/clsn/2__Slide5.JPG

Liver cancer expected to be the Number 1 cancer by 2020
http://www.wsw.com/webcast/cowen3/clsn/2__Slide9.JPG

Strong Patent till 2018
http://www.wsw.com/webcast/cowen3/clsn/2__Slide4.JPG

Commercialization strategy
http://www.wsw.com/webcast/cowen3/clsn/2__Slide22.JPG

Financial summary
http://www.wsw.com/webcast/cowen3/clsn/2__Slide23.JPG

[FavStocks]

You got a great track record BiotechMaster. TLON is doing great and I like this one with all the news coming up.

[The Follower]

I bought in yesterday, and this guy definitely has a very good track record...
I hope this one to reach anywhere near the 6$ mark.

[The Follower]

Broke resistance at 3$ today, up in after market to 3.25$!
Already a 10% in the basket, another very good tip from BiotechMaster!

[BiotechMaster]

Still a great buying opp....

New Article out today ..Perfect timing lol

http://www.otcstockreview.com/CLSN_Review.pdf

OTC Stock Review announces that it has initiated coverage of Celsion Corporation (Nasdaq:CLSN - News), a Phase III oncology focused company addressing the largest unmet need in cancer, HCC, or primary liver cancer. In our opinion, with a market cap of only $43 million, CLSN is undervalued when compared to its peers. Not only is the stock undervalued, but we believe CLSN could trade into the upper end of its trading range, and possibly make new 52 week highs, as the Company gains investor notoriety from results of its clinical trials.

CLSN has developed a technology that provides highly effective targeted delivery of chemotherapeutics. The foundation of Celsion's oncology platform is ThermoDox, a heat-sensitive liposome that Celsion has licensed from Duke University. Celsion and Duke University have developed the liposomal formulation encapsulating doxorubicin and Celsion is currently conducting ThermoDox trials for Hepatocellular Carcinoma (HCC), also referred to as primary liver cancer, and recurrent chest wall (RCW) breast cancer. ThermoDox, which represents a billion dollar global market opportunity, is in a Phase III pivotal trial with near-term commercial potential known as the HEAT Study.

Not only is the prospect of saving lives very great, but CLSN is three to four months from a planned interim analysis and approximately 12 months from top line data in an 11 country, 600 patient, global trial evaluating its first drug, ThermoDox, in the largest unmet medical need left in oncology. Our report includes a list of near-term milestones & catalysts, so investors can follow CLSN's progress.